AMD Drugs Market - 2021-2031
The AMD Drugs Market was valued at US$ 9,717.64 million in 2021 and is anticipated to reach US$ 15,903.86 million by 2031, at a CAGR of 0.0726 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the AMD Drugs Market.
This report delivers a comprehensive overview of the AMD Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding AMD Drugs Market. The AMD Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2031.
AMD Drugs Market Scope:
By Product Type
This report delivers a comprehensive overview of the AMD Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding AMD Drugs Market. The AMD Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the AMD Drugs Market.
This report delivers a comprehensive overview of the AMD Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding AMD Drugs Market. The AMD Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2031.
AMD Drugs Market Scope:
By Product Type
- Wet AMD
- Dry AMD
- Eylea
- Lucentis
- Beovu
- Avastin
- Macugen
- Others
- Intravitreal
- Intravenous
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Bayer HealthCare LLC
- F. Hoffmann-La Roche Ltd.
- Regeneron Pharmaceuticals, Inc.
- Novartis AG
- Pfizer Inc.
- Kubota Pharmaceutical Holdings Inc.
- AbbVie Inc.
- Kodiak Sciences
- Genentech Inc., Roche Group Member
- Regenxbio Inc.(LIST NOT EXHAUSTIVE)
This report delivers a comprehensive overview of the AMD Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding AMD Drugs Market. The AMD Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. MARKET METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. The rising novel product launches
4.1.1.2. Increasing regulatory approvals
4.1.2. Restraints:
4.1.2.1. High cost associated with AMD drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Forces
5.2. Unmet Needs
5.3. Supply chain Analysis
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. BY PRODUCT TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Wet AMD*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Dry AMD
8. BY DRUG TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Eylea*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Lucentis
8.4. Beovu
8.5. Avastin
8.6. Macugen
8.7. Others
9. BY ROUTE OF ADMINISTRATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Intravitreal*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Intravenous
10. BY DISTRIBUTION CHANNEL
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospitals Pharmacies *
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. The U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Distribution Channel
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12. COMPETITIVE LANDSCAPE
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
12.4. List of Key Companies to Watch
13. COMPANY PROFILES
13.1. Bayer HealthCare LLC
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. F. Hoffmann-La Roche Ltd.
13.3. Regeneron Pharmaceuticals, Inc.
13.4. Novartis AG
13.5. Pfizer Inc.
13.6. Kubota Pharmaceutical Holdings Inc.
13.7. AbbVie Inc.
13.8. Kodiak Sciences
13.9. Genentech Inc., Roche Group Member
13.10. Regenxbio Inc.(*LIST NOT EXHAUSTIVE)
14. DATAM INTELLIGENCE
14.1. Appendix
14.2. About Us and Services
14.3. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. The rising novel product launches
4.1.1.2. Increasing regulatory approvals
4.1.2. Restraints:
4.1.2.1. High cost associated with AMD drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Forces
5.2. Unmet Needs
5.3. Supply chain Analysis
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. BY PRODUCT TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Wet AMD*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Dry AMD
8. BY DRUG TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Eylea*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Lucentis
8.4. Beovu
8.5. Avastin
8.6. Macugen
8.7. Others
9. BY ROUTE OF ADMINISTRATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Intravitreal*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Intravenous
10. BY DISTRIBUTION CHANNEL
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospitals Pharmacies *
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. The U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Distribution Channel
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12. COMPETITIVE LANDSCAPE
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
12.4. List of Key Companies to Watch
13. COMPANY PROFILES
13.1. Bayer HealthCare LLC
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. F. Hoffmann-La Roche Ltd.
13.3. Regeneron Pharmaceuticals, Inc.
13.4. Novartis AG
13.5. Pfizer Inc.
13.6. Kubota Pharmaceutical Holdings Inc.
13.7. AbbVie Inc.
13.8. Kodiak Sciences
13.9. Genentech Inc., Roche Group Member
13.10. Regenxbio Inc.(*LIST NOT EXHAUSTIVE)
14. DATAM INTELLIGENCE
14.1. Appendix
14.2. About Us and Services
14.3. Contact Us
